Lipoprotein-associated phospholipase A2 and coronary heart disease
10.3760/cma.j.issn.1009-9158.2015.07.018
- VernacularTitle:脂蛋白相关性磷脂酶A2与冠心病相关性研究进展
- Author:
Tongge ZHANG
;
Mei JIA
- Publication Type:Journal Article
- Keywords:
Lp-PLA2;
CHD;
Atherosclerosis;
Darapladib
- From:
Chinese Journal of Laboratory Medicine
2015;(7):493-497
- CountryChina
- Language:Chinese
-
Abstract:
Lp-PLA2 is widely concerned in recent years as a vascular inflammation factor that plays an important role in the development of atherosclerosis .The level of plasma Lp-PLA2 is related to the stability of carotid artery atherosclerotic plaque .it is an independent predictor of coronary heart disease risk . Its specific inhibitor Darapladib also becomes a hotspot of clinical cardiovascular pharmaceutical research . However,two randomized, placebo-controlled, double-blind, international, multicenter, event-driven trials, STABILITY and SOLID-TIMI 52, have shown that Darapladib could not significantly reduce the risk of cardiovascular events.
